Express Scripts Holding (NASDAQ:ESRX)‘s stock had its “neutral” rating reaffirmed by Zacks in a report issued on Monday, ARN reports. They currently have a $64.00 price objective on the stock. Zacks‘ price objective points to a potential upside of 5.12% from the company’s current price.
Zacks‘ analyst wrote, “Express Script posted third quarter earnings per share of $1.08, up from $1.03 reported in the year-ago quarter. The Zacks Consensus Estimate was $1.08. Revenues were down 3.2% year over year to $25.9 billion but surpassed the Zacks Consensus Estimate of $25.0 billion. The decrease in revenues was attributed to lower claims volume owing to the transition of claims of UnitedHealthcare Group. Express Scripts now expects adjusted earnings around $4.30 – $4.34 per share in 2013 compared to the earlier estimate of $4.26 – $4.34 per share. The third quarter results were encouraging. However, the introduction of insurance exchanges, additional costly regulations, escalation of brand drug prices and increased specialty drug utilization loom large in the long run. Hence, we maintain a Neutral recommendation. “
Shares of Express Scripts Holding (NASDAQ:ESRX) traded up 0.99% during mid-day trading on Monday, hitting $61.48. The stock had a trading volume of 2,670,727 shares. Express Scripts Holding has a one year low of $49.79 and a one year high of $67.66. The stock’s 50-day moving average is $65.13 and its 200-day moving average is $61.71. The company has a market cap of $49.541 billion and a price-to-earnings ratio of 27.37. Express Scripts Holding also was the target of unusually large options trading on Friday. Traders bought 31,850 call options on the company. This is an increase of approximately 538% compared to the typical volume of 4,995 call options.
Express Scripts Holding (NASDAQ:ESRX) last announced its earnings results on Friday, October 25th. The company reported $1.08 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.08. The company had revenue of $25.92 billion for the quarter, compared to the consensus estimate of $25.01 billion. During the same quarter last year, the company posted $1.02 earnings per share. Express Scripts Holding’s revenue was down 3.2% compared to the same quarter last year. Analysts expect that Express Scripts Holding will post $4.32 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on ESRX. Analysts at Thomson Reuters/Verus upgraded shares of Express Scripts Holding from a “hold” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at FBR & Co. upgraded shares of Express Scripts Holding from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday. Finally, analysts at FBR Capital Markets initiated coverage on shares of Express Scripts Holding in a research note to investors on Thursday. They set an “outperform” rating and a $75.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $69.74.
Express Scripts, Inc is a pharmacy benefit management (NASDAQ:ESRX) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.